Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $28.5 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 90.89% year-over-year to $28.5 million; the TTM value through Sep 2025 reached $74.1 million, up 97.73%, while the annual FY2024 figure was $42.6 million, 31.93% down from the prior year.
  • Change in Acquisitions & Divestments reached $28.5 million in Q3 2025 per CRVS's latest filing, up from $19.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $28.5 million in Q3 2025 and bottomed at $810000.0 in Q1 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $13.9 million, with a median of $14.9 million recorded in 2024.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 2088.27% in 2023, then tumbled 73.93% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $15.4 million in 2022, then tumbled by 40.85% to $9.1 million in 2023, then skyrocketed by 56.73% to $14.3 million in 2024, then surged by 99.89% to $28.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $28.5 million in Q3 2025, $19.3 million in Q2 2025, and $12.0 million in Q1 2025.